Retinitis Pigmentosa Clinical Trial
Official title:
Calibration of Visual Function Evaluation Tests in Patients With Severe Vision Loss
NCT number | NCT03626207 |
Other study ID # | CLR180001 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | October 4, 2018 |
Est. completion date | June 26, 2019 |
Verified date | July 2019 |
Source | Astellas Pharma Inc |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The objective of this study is to develop the comprehensive visual function evaluation method in severe visually impaired patient.
Status | Completed |
Enrollment | 8 |
Est. completion date | June 26, 2019 |
Est. primary completion date | June 26, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years and older |
Eligibility |
Inclusion Criteria: - Subjects with severe visual disturbance (count-fingers or worse vision for severe eyes) at the time of obtaining the consent and at screening Exclusion Criteria: - Subjects should not have participated in any other clinical trial or clinical study involving visual function evaluation within 6 months - History of surgery, past history, and complications (cardiac/ hepatic/ renal/ respiratory/ hematological diseases, optic nerve diseases causing marked loss of visual field, and uveitis etc.) that potentially affect evaluation and safety of the study - Pregnant women - Subjects who are judged that continuation of the study is difficult during the study period - Subjects who are employed by the company sponsoring this study, an organization or institution related to this study |
Country | Name | City | State |
---|---|---|---|
Japan | Site JP00001 | Kobe | Hyogo |
Lead Sponsor | Collaborator |
---|---|
Astellas Pharma Inc |
Japan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Slit-lamp-microscopy | To assess the visual function. | Up to 3 months | |
Primary | Optical Coherence Tomography (OCT) test | To assess the visual function. | Day 1 | |
Primary | Early Treatment Diabetic Retinopathy Study (ETDRS) | To assess the visual function. | Up to 3 months | |
Primary | The 25-item National Eye Institute Visual Function Questionnaire (NEI VFQ-25) | NEI VFQ 25 is a questionnaire intended to measure visual function and quality of life. It has 25 questions. The original response of each item are coded as per the NEI VFQ scoring system ranging from 0 (worst) to 100 (best). | Up to 3 months | |
Primary | The 11-item National Eye Institute Visual Function Questionnaire (NEI VFQ-11) | NEI VFQ 11 is a questionnaire intended to measure visual function and quality of life. It has 11 questions. The original response of each item are coded as per the NEI VFQ scoring system ranging from 0 (worst) to 100 (best). | Up to 3 months | |
Primary | Nottingham Adjustment Scale Japanese Version (NAS-J) | NAS-J is the Japanese version of NAS which measures psychological adjustment to the visual impairment, and to assess its validity and reliability. The NAS is composed of 7 psychological subscales including anxiety-depression, self-esteem, attitude to disability, locus of control, acceptance of disability, self-efficacy and attributional style. The original response of each item are coded as per the NAS-J scoring system ranging from 0 (lowest psychological adjustment) to 100 (highest psychological adjustment). | Up to 3 months | |
Primary | Daily living task dependent on vision (DLTV) questionnaire | DLTV is a quality of life questionnaire composed of 22 items to obtain estimates of self-reported ability to perform vision-related tasks in persons with visual impairment. Participants rate items on a four-point scale, with "Can't see to do" (score, 1), "A lot of difficulty" (score, 2), "A little difficulty" (score, 3), and"No difficulty" (score, 4). The original response of each item are coded as per the DLTV scoring system ranging from 0 (worst) to 100 (best). | Up to 3 months | |
Primary | Table test | To assess the visual function. | Up to 3 months | |
Primary | Monitor test | To assess the visual function. | Up to 3 months | |
Primary | Pupillary function test | To assess the visual function. | Up to 3 months | |
Primary | Full field stimulus threshold testing (FST) | To assess the visual function. | Up to 3 months | |
Primary | White flash visual evoked potential (VEP) test | To assess the visual function. | Up to 3 months | |
Primary | Color flash VEP test | To assess the visual function. | Up to 3 months | |
Primary | Electrically evoked response (EER) test | To assess the visual function. | Up to 3 months | |
Primary | White flash Electroretinography (ERG) test | To assess the visual function. | Day 1 | |
Primary | Multifocal ERG test | To assess the visual function. | Up to 3 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT01432847 -
Cell Collection to Study Eye Diseases
|
||
Completed |
NCT04983914 -
Retrospective NIS to Evaluate the Patient Benefit of TES
|
||
Recruiting |
NCT03845218 -
Retinitis Pigmentosa Clinical Measures and Repeatability Testing of Potential Outcome Measures
|
||
Completed |
NCT00231010 -
Molecular Genetics of Retinal Degenerations
|
||
Active, not recruiting |
NCT04611503 -
PDE6A Gene Therapy for Retinitis Pigmentosa
|
Phase 1/Phase 2 | |
Completed |
NCT02909985 -
Visual Activity Evoked by Infrared in Humans After Dark Adaptation
|
N/A | |
Recruiting |
NCT01914913 -
Clinical Study to Evaluate Safety and Efficacy of BMMNC in Retinitis Pigmentosa
|
Phase 1/Phase 2 | |
Completed |
NCT01949623 -
Biomarkers In Retinitis Pigmentosa (BIRP)
|
N/A | |
Completed |
NCT01835002 -
Transcorneal Electrical Stimulation - Multicenter Safety Study
|
N/A | |
Completed |
NCT00407602 -
Argus® II Retinal Stimulation System Feasibility Protocol
|
N/A | |
Completed |
NCT00515814 -
Retina Implant Pilot Trial to Evaluate Safety & Efficacy in Blind Patients Having Degenerated Photo-receptors
|
N/A | |
Completed |
NCT00100230 -
DHA and X-Linked Retinitis Pigmentosa
|
Phase 2 | |
Active, not recruiting |
NCT00378742 -
Repository for Inherited Eye Diseases
|
||
Terminated |
NCT05085964 -
An Open-Label Extension Study to Evaluate Safety & Tolerability of QR-421a in Subjects With Retinitis Pigmentosa
|
Phase 2 | |
Recruiting |
NCT05805007 -
Safety and Tolerability Study of Gene Editing Drug ZVS203e in Participants With Retinitis Pigmentosa
|
Early Phase 1 | |
Recruiting |
NCT05909488 -
Role of UC-MSC and CM to Inhibit Vision Loss in Retinitis Pigmentosa Phase I/II
|
Phase 2/Phase 3 | |
Recruiting |
NCT06291935 -
Safety and Tolerability of Intravitreal Administration of VG901 in Patients With Retinitis Pigmentosa Due to Mutations in the CNGA1 Gene
|
Phase 1 | |
Recruiting |
NCT03078309 -
The Effects of Cannabis on Visual Functions in Healthy and Retinitis Pigmentosa Patients
|
Early Phase 1 | |
Completed |
NCT04238858 -
Effects of Subtenon-injected Autologous Platelet-rich Plasma on Visual Functions in Eyes With Retinitis Pigmentosa
|
N/A | |
Active, not recruiting |
NCT01680510 -
The Effect of Oral Administration of 9-cis β Carotene Rich Powder of the Alga Dunaliella Bardawil
|
Phase 1/Phase 2 |